The board of directors of Atmofizer Technologies Inc. (the “Company” or “Atmofizer”) has authorised a share consolidation of the Company’s common shares (“Common Shares”) on a twenty (20) for one (1) basis (the “Consolidation”). 133,747,806 Common Shares are issued and outstanding on a non-diluted basis out of the Company’s total number of Common Shares without a par value that are currently part of the permitted share structure. Following consolidation, the company is anticipated to have 6,687,390 Common Shares issued and outstanding on a non-diluted basis, subject to rounding. Because shareholder approval is not needed for the consolidation in accordance with the Business Corporations Act (British Columbia) and the company’s articles, the company won’t ask shareholders for their consent. A later news release will contain additional information about the Consolidation.
With regards to Atmofizer Technologies Inc.
Based on its patent-protected and patent-pending technology for ultrafine particle agglomeration and neutralisation, Atmofizer’s consumer and commercial solutions. The wide spectrum of harmful nano-scale particles, viruses, and bacteria that can no longer be efficiently controlled by standard HEPA filters and UV lights are addressed by this capability in an innovative and more effective way. By increasing air safety and purifying effectiveness while reducing clients’ operational expenses, Atmofizer intends to upend the air treatment sector.

Source: Prnewswire